Novartis pulls the plug on UK-based cardiovascular study

Nicole DeFeudis

Editor

Novartis is calling off a UK-based trial for Leqvio in the primary prevention of cardiovascular events in patients with high cholesterol, the company confirmed on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis pulls the plug on UK-based cardiovascular study

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­var­tis pulls the plug on UK-based car­dio­vas­cu­lar study

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis pulls the plug on UK-based cardiovascular study